<DOC>
	<DOC>NCT02103283</DOC>
	<brief_summary>A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.</brief_summary>
	<brief_title>A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)</brief_title>
	<detailed_description>A Phase 1, Open-Label Safety and Pharmacodynamic Study of RV 001, an Insulin-Like Growth Factor-1 Receptor (IGF-1) Antagonist, Given By IV Infusion in Patients with Diabetic Macular Edema (DME).</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Diagnosis of diabetes mellitus with Hemoglobin A1c &lt;8.5% IGF 1 in serum &gt; 106 ng/mL Women of childbearing potential must have negative pregnancy test and be willing and able to use two different methods of contraception, one of which must be oral contraceptive or depot formulation. Males must be surgically sterile or agree to use barrier contraception Clinically significant DME of less than 12 months duration Nonproliferative diabetic retinopathy of moderate severity Best corrected electronic ETDRS letter score &lt; 78 and &gt; 24 Unstableuncontrolled diabetes as demonstrated by a change in diabetes medication greater than 15% in the previous 60 days. Significant renal disease, myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure Blood pressure &gt; 180/110 Antivascular endothelial growth factor (VEGF) treatment within two months prior to enrollment History of pan retinal photocoagulation within four months prior to enrollment History of ocular surgery within four months prior to enrollment History of systemic treatment with corticosteroids within 3 months prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>